Skip to search formSkip to main contentSkip to account menu

Anti-OX40 Monoclonal Antibody MOXR0916

Known as: MOXR0916 
An agonistic humanized monoclonal antibody against the receptor, OX40 (CD134), with potential immunostimulatory and antineoplastic activities. Upon… 
National Institutes of Health

Related topics

Related topics

4 relations
Antibody-Dependent Cellular CytotoxicityB-LymphocytesCytotoxic T-Lymphocytesantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.
101Background: OX40 is a co-stimulatory receptor that is transiently expressed by T cells upon antigen recognition. In murine… 
2016
2016
Abstract CT097: A first-in-human phase I dose escalation study of the OX40 agonist MOXR0916 in patients with refractory solid tumors
Background: OX40 is a co-stimulatory receptor that is transiently expressed by T cells upon antigen recognition. In murine models… 
2014
2014
424 Nonclinical safety assessment of a humanized anti-OX40 agonist antibody, MOXR0916
2014
2014
209 Pre-clinical and translational pharmacology, pharmacokinetics and pharmacodynamics for a humanized anti-OX40 antibody MOXR0916, a T-cell agonist in the treatment of solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)